Evaluation of ONYX in ENDOVASCULAR Treatment of Cerebral AVMs

Evaluation of ONYX in ENDOVASCULAR Treatment of Cerebral AVMs. Prospective, Multi-center and Observational French Study

To assess safety and efficacy of ONYX treatment for cAVM:

The main objective of this study is to assess the safety at 1 month after any embolization session and the efficacy at:

• 12 months post last embolization in case of treatment with embolization only
• 12 months after additional treatment with neurosurgery
• 36 months after additional treatment with radiosurgery

Inclusion Criteria:

• The patient presents a cerebral AVM (not already treated) that can be treated by embolization with Onyx whether or not associated with a cyanoacrylate based adhesive,
• The patient is at least 6 years old.

Exclusion Criteria:

• During the treatment period for his/her cerebral AVM, the patient participates in a study assessing another medical device, another procedure or a drug.
• The patient and/or his/her legal representative (if applicable) refuses to give his/her consent to the collection and processing of data required by the centralized follow-up. For patients who refused collection of their personal data, only, the reason for non inclusion and date of implantation will be documented.
• Any condition that could prevent follow-up of the patient.